AVROBIO INC
COM · CUSIP 05455M100
1
institutional holders
-47 vs Q1 2024
531
shares reported held*
$9.0kreported value*
0 new
0 added
1 reduced
47 sold out
net sold ≈ $506.3m (-29.9m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $16.95.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 54 |
| Q4 2022 | 46 |
| Q1 2023 | 50 |
| Q2 2023 | 42 |
| Q3 2023 | 49 |
| Q4 2023 | 46 |
| Q1 2024 | 48 |
| Q2 2024 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 13 | 29 |
| Q1 2023 | 24 | 20 |
| Q2 2023 | 14 | 24 |
| Q3 2023 | 26 | 19 |
| Q4 2023 | 17 | 18 |
| Q1 2024 | 19 | 21 |
| Q2 2024 | 0 | 48 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
CallsPuts
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2023 | $249.4k | $1.1k | 0.00 |
| Q4 2023 | $175.1k | $952 | 0.01 |
| Q1 2024 | $72.4k | $128 | 0.00 |
| Q2 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| Atlas Venture Life Science Advisors, LLC | Sold out | -4.5m |
| BML Capital Management, LLC | Sold out | -4.0m |
| ADAR1 Capital Management, LLC | Sold out | -4.0m |
| FMR LLC | Sold out | -2.0m |
| Verition Fund Management LLC | Sold out | -1.9m |
| VANGUARD GROUP INC | Sold out | -1.9m |
| ACADIAN ASSET MANAGEMENT LLC | Sold out | -1.2m |
| Newtyn Management, LLC | Sold out | -1.1m |
| Aisling Capital Management LP | Sold out | -1.0m |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -888.2k |
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| CWM, LLC 0.00% of their portfolio | 531 $9.0k | Reduced -5.9k |